Development of a New Class of Broad-Stage Antimalarial Agents

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/2000087

Funding Status
Status not available

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

In 2017, there were almost 220 million cases of malaria across 90 different countries, associated with 435,000 deaths, and with 65-70% of all malaria deaths tragically being children under the age of 5 years old. No significant progress in reducing global malaria cases has been made over the last 4 years and the need for new and better treatments remains dire. In this research and development plan, we will develop novel and safer drugs for the treatment of drug resistant malaria.

Funded Activity Details

Start Date: 01-01-2020

End Date: End date not available

Funding Scheme: Development Grants

Funding Amount: $729,037.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

drug development | malaria drug resistance | medicinal chemistry | pharmaceutical treatment

Related Links